medigraphic.com
Academia Mexicana de Neurología, A.C.

2013, Número 1

<< Anterior Siguiente >>

Rev Mex Neuroci 2013; 14 (1)


Actualidades en las aplicaciones clínicas de la melatonina en trastornos del sueño

Jiménez-Genchi A, Guarneros-Roniger DD, Barrera-Medina A, Laurel-Gardeazábal IE

Idioma: Español
Referencias bibliográficas: 38
Paginas: 39-43
Archivo PDF: 197.67 Kb.


RESUMEN

La melatonina es una hormona indolamina producida por la glándula pineal y cuya secreción determinada por la ausencia de la luz sigue un ritmo circadiano. A través de su unión a los receptores MTI y MT2 en el núcleo supraquiasmático ejerce sus efectos de promoción del sueño y cronobióticos. Estas propiedades le confieren utilidad clínica en el tratamiento del insomnio, el síndrome de fase retrasada de sueño, síndrome de Jet Lag y posiblemente en el trastorno por cambios de turno laboral. Asimismo, se ha documentado su uso en una parasomnia conocida como trastorno de conducta en sueño MOR. Existen otros fármacos agonistas de los receptores a melatonina como el ramelteon, agomelatina y tasimelteon con efectos sobre el sueño similares a los producidos por la melatonina.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Lerner A, Case JD, Takahashi Y. Isolation of melatonin and 5-Methoxyindole. J Biol Chem 1960; 235: 1992-7.

  2. Axelrod J. The pineal gland: a neurochemical transducer. Science 1974; 184: 1341-8.

  3. Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 1991; 12: 151-80.

  4. Benitez-King G. Melatonina: Un Destello de Vida en la Oscuridad. México: Fondo de Cultura Económica; 2008.

  5. Ebadi M, Govitrapong P. Neural pathways and neurotransmitters affecting melatonin synthesis. J Neural Trans 1986: 21(Suppl.): 125-55.

  6. Pandi-Perumal SR, Srinivasan V, Maestroni GJM, Cardinali DP, Poeggeler B, Hardeland R. Melatonin. Nature’s most versatile biological signal? FEBS J 2006; 273: 2813-38.

  7. Reppert SM. Melatonin receptors: molecular biology of a new family of G protein-coupled receptors. J Biol Rhythms 1997; 12: 528-31.

  8. Pévet P, Bothorel B, Slotten H, Saboureau M. The chronobiotic properties of melatonin. Cell Tissue Res 2002; 309: 183-91.

  9. Moore RY. The circadian system and sleep-wake behavior. In: Sleep and Biological Rhythms. Montplaisir J, Godbout R (eds.). Oxford University Press: New York, 1990.

  10. Arendt J, Skena DJ. Melatonin as a chronobiotic. Sleep Med Rev 2005: 9: 25-39.

  11. Morgenthaler TI, Lee-Chiong T, Alessi C, Friedman L, Aurora N, Boehlecke B, et al. Standards of Practice Committee of the AASM. Practice Parameters for the clinical evaluation and treatment of circadian rhythm sleep disorders. Sleep 2007; 30: 1445-59.

  12. Burgess HJ, Sharkey KM, Eastman CI. Bright light, dark and melatonin can promote circadian adaptation in night shift workers. Sleep Med Rev 2002; 6: 407-20.

  13. Anton-Tay F, Díaz JL, Fernández-Guardiola A. On the effect of melatonin upon human brain. Its possible therapeutic implications. Life Sci 1971; 10: 841-50.

  14. Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, et al. The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med 2005; 20: 1151-8.

  15. Brzezinski A, Vangel MG, Wurtman RJ, Norrie G, Zhdanova I, Ben-Shushan A, et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 2005; 9: 41-50.

  16. Hardeland R. New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatonergic agonists. Neuropsychiatr Dis Treat 2009; 5: 341-54.

  17. Arendt J, Rajaratnam SMW. Melatonin and its agonists: an update. Br J Psychiatry 2008; 193; 267-9.

  18. Wade A, Zisapel N, Lemoine P. Prolonged-release melatonin for the treatment of insomnia: targeting quality of sleep and morning alertness. Aging Health 2008; 4: 11-21.

  19. Lemoine P, Nir T, Laudon M, Zisapel N. Prolonged-release melatonin improves sleep quality an morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res 2007; 16: 372-80.

  20. Smith MT, Perlis ML, Park A, Smith MS, Pennington J, Giles D, et al. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry 2002; 159: 5-11.

  21. Holbrook AM, Crwother R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of insomia. CMAJ 2000;162: 225-33.

  22. Buscemi N, Vandermeer B, Friesen C, Blaly L, Tubman M, Ospina M, et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J Gen Intern Med 2007; 22: 1335-50.

  23. Trotti LM. REM sleep behavior disorder in older individuals: epidemiology, pathophysiology, and management. Drugs Aging 2010; 27(6): 457-70.

  24. Anderson NK, D. Phil. Drug treatment of REM sleep behavior disorder: the use of drug therapies other than clonazepam. J Clin Sleep Med 2009; 5(3): 235-9.

  25. Kunz D, Mahlberg R. A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behavior disorder. J Sleep Res 2010; 19: 591-6.

  26. Rajaratman SMW, Middleton B, Stone BM, Arent J, Dijk Derk-Jan. Melatonin advances the circadian timing of EEG sleep and directly facilitates sleep without altering its duration in extended sleep opportunities in humans. J Physiol 2004: 561(1): 339-51.

  27. Boeve FB, Silber HM, Ferman TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med 2003; 4(3): 281-4.

  28. Takeuchi N, Uchimura N, Hashizume Y, Mukai M, Etoh Y, Yamamoto K, et al. Melatonin treatment for REM sleep behavior disorder. Psychiatry Clin Neurosci 2001; 55(3): 267-9.

  29. Pandi-Perumal SR, Srinivasan V, Poeggeler B, Hardeland R, Cardinali DP. Drug insight: The use of melatonergic agonists for the treatment of insomniafocus on ramelteon. Nat Clin Pract Neurol 2007; 3(4): 221-8.

  30. Srinivasan V, Pandi-Perumal SR, Trahkt I, Spence DW, Poeggeler B, Hardeland R, et al. Melatonin and melatonergic drugs on sleep: possible mechanism of action. Int J Neurosci 2009; 119(6): 821-49.

  31. Markwald RR, Lee-Chiong TL, Burke TM, Snider JA, Wright KP Jr. Effects of the melatonin MT1/MT2 Agonist Ramelteon on daytime body temperature and sleep. Sleep 2010; 33(6): 825-31.

  32. Bourin M, Prica C. Melatonin receptor agonist agomelatine: a new drug for treating unipolar depression. Curr Pharm Des 2009; 15(14): 1675-82.

  33. McAllister-Williams RH, Baldwin DS, Haddad PM, Bazire S. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol 2010; 25(2): 95-102.

  34. Rajaratnam, SMW, Cohen DA, Rogers NL. Melatonin and melatonin analogues. Sleep Med Clin 2009; 4(2): 179-93.

  35. Fornaro M, Prestia D, Colicchio S, Perugi G. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Curr Neuropharmacol 2010; 8(3): 278-304.

  36. Quera SMA, Vanier B, Laredo J, Hartley S, Chapotot F, Moulin C, et al. Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int J Neuropsychopharmacol 2007; 10(5): 691-6.

  37. Loo H, Hale A, D’haenen H. Determination of the dose of agomelatine, a melatoninergic selective 5HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002; 17(5): 239-47.

  38. Vachharajani NN, Yeleswaram K, Boulton DW. Preclinical pharmacokinetics and metabolism of BMS-214778, a novel melatonin receptor agonist. J Pharm Sci 2003; 92(4): 760-72.




2020     |     www.medigraphic.com